Theralase Demonstrates Activation of Rutherrin with Diabetes Drug

Toronto-based Theralase Technologies Inc. has revealed preclinical findings demonstrating that its leading drug formulation, Rutherrin, can be activated by Metformin, a common diabetes medication, without the need for light or radiation. This combination has shown to significantly increase Reactive Oxygen Species (ROS) production, crucial for cancer cell destruction.

Metformin, approved by the FDA in 1994 for Type 2 diabetes, has been found to work in synergy with Rutherrin, enabling it to cross critical blood barriers and target cancer cells throughout the body, including the brain. This discovery opens new avenues for treating cancers with Rutherrin outside of traditional hospital settings.

Theralase plans to commence clinical studies, pending regulatory approval and toxicology analysis, to explore the full therapeutic potential of this drug combination. The clinical applications of Rutherrin may expand significantly, offering more flexible and less costly treatment options for patients with various cancers.